Key facts
- It has raised $20.0M; the latest was Seed Round ($10.0M) in May 2025.
- Notable investors include Type One Ventures, Goldcrest Capital, Venture Science, Godfrey Capital, Adam Ross — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Junevity
- ·The full record, as it builds
Funding rounds
No funding rounds for Junevity are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Junevity
Operator of a biotechnology company intended to develop cell reset therapeutics for longevity. The company's platform uses large-scale human data and artificial intelligence to identify transcription factor targets and repress them with small interfering RNA therapeutics, enabling healthcare industry with medications for underserved and severe rewinding diseases of aging with novel transcription factor medicines.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Employees
- 13
- Website
- junevity.com/
- Ownership
- Privately Held (backing)
Junevity doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Junevity shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Junevity in its N-PORT filings yet. We sweep new filings monthly.